Transgene Biotek is currently trading at its upper circuit limit of Rs. 2.82, up by 0.13 points or 4.83% from its previous closing of Rs. 2.69 on the BSE.
The scrip opened at Rs. 2.82 and has touched a high and low of Rs. 2.82 and Rs. 2.82 respectively. So far 13250 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 7.40 on 22-Aug-2014 and a 52 week low of Rs. 1.71 on 30-Mar-2015.
Last one week high and low of the scrip stood at Rs. 2.69 and Rs. 2.22 respectively. The current market cap of the company is Rs. 21.37 crore.
The promoters holding in the company stood at 21.68% while Non-Institutions held 70.04% stake in the company.
Transgene Biotek has received patent in the US for its novel molecule to be developed for treatment of liver cancer. The company’s novel molecule ‘miRNA 101’ for therapy against liver cancer has been allowed for issuance of a USA patent after the prosecution on merits have been closed.
The company’s current product portfolio covers segments such as oncology, auto-immunity, drug delivery and bio-generics. This granting of USA patent is a significant step in moving ahead with the development of this novel drug.
Transgene Biotek is involved in the development of several cutting edge technologies. The company is engaged in manufacturing drugs for New Drug Delivery System (NDDS), Biogeneries and Human Vaccines.
Company Name | CMP |
---|---|
Apollo Hospital Ent. | 7036.65 |
Max Healthcare Inst | 1006.75 |
Narayana Hrudayalay | 1249.35 |
Aster DM Healthcare | 444.55 |
Global Health | 1115.50 |
View more.. |